By Bernadette Toner and Turna Ray
SAN FRANCISCO — A Novartis official said yesterday that the company has identified a genetic marker that it plans to market as a companion diagnostic for a COX-2 inhibitor that was previously withdrawn from several non-US markets due to liver toxicity issues.
Registering provides access to this and other free content.
Already have an account?Login Now.
In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.
A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.
As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.
The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.